Minghui Pharmaceutical ( Minghui ), a late-stage clinical biopharmaceutical company, announced the closing of a $131 million ...

Emerging therapies targeting GD2, a marker highly expressed in neuroblastoma, offer tremendous promise. FDA-approved ...